表 2. Global research hotspots on oncology: basic research and epidemiological research.
肿瘤领域全球研究热点——基础与流行病学
| 研究主题 | 相关研究 | 被引次数
查询时间 2020.09.23 |
期刊来源 |
| 肿瘤领域基础研究 | |||
| 免疫检查点抑制剂治疗肿瘤的不良事件 | Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[4] | 436 | Clin Cancer Res |
| Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens：a systematic review and meta-analysis[5] | 194 | JAMA Oncol | |
| Fatal toxic effects associated with immune checkpoint inhibitors：a systematic review and meta-analysis[6] | 295 | JAMA Oncol | |
| Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials：a systematic review and meta-analysis[7] | 87 | JAMA Oncol | |
| 长链非编码 RNA 和 micro RNA | Long non-coding RNA LINC00339 facilitates the tumorigenesis of non-small cell lung cancer by sponging miR-145 through targeting FOXM1[8] | 31 | Biomed Pharmacother |
| Phase I study of MRX34，a liposomal miR-34a mimic，administered twice weekly in patients with advanced solid tumors[9] | 284 | Invest New Drugs | |
| Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells[10] | 68 | Int J Nanomed | |
| HER 激酶抑制剂 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers[11] | 198 | Nature |
| 木耳菜 | Antiangiogenic phenylpropanoid glycosides from gynura cusimbua[12] | 6 | Nat Prod Res |
| 肿瘤特异性抗原 | Noncoding regions are the main source of targetable tumor-specific antigens[13] | 72 | Sci Transl Med |
| 肿瘤流行病学 | |||
| 全球 | Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）： analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[14] | 733 | Lancet |
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[1] | 15 033 | CA Cancer J Clin | |
| 美国 | Cancer screening in the United States，2017：A review of current American cancer society guidelines and current issues in cancer screening[15] | 214 | CA Cancer J Clin |
| Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States[16] | 219 | CA Cancer J Clin | |